Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Abnova, Adjuvance, Adma, Aetion, Airway, Amarin, Ampio, Bayer, Be The Match, Beigene, Beximco, Cansino, Celonic, Celularity, Centivax, Cytodyn, Generex, Genexine, Genocea, Glaxosmithkline, Hoth, I-Mab, IMV, Innocan, Innovation, Innovent Biologics, Inovio, Iqvia, Kindred, Kleo, Medison, Nanoviricides, Nantkwest, Oragenics, Orion, Pharmajet, Precision Nanosystems, Prellis Biologics, Primary Peptides, Progenabiome, Promis Neurosciences, Qingdao Primedicine, Rising, Samsung Biologics, Shionogi, Takara, Vanda, Vaxart.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Biosig Technologies, Calcimedica, Dynavax Technologies, Octant, Sinovac Biotech, Windtree Therapeutics.
The latest global regulatory news, changes and updates affecting biopharma, including: Biomedical Advanced Research and Development Authority, EMA, FDA, House Energy and Commerce Subcommittee on Oversight and Investigations, International Coalition of Medicines Regulatory Authorities, National Institutes of Health, Trump administration, World Health Organization.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Antisense, Arch Biopartners, Covis, Daiichi Sankyo, Diffusion, Incyte, Mezzion.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Anavex Life Sciences, Appili, Astellas, Astrazeneca, Atea, Beigene, Calcimedica, Daiichi Sankyo, Fibrogen, Genexine, I-Mab Biopharma, Octapharma USA, Organicell Regenerative Medicine.